Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 61, Issue 1-2, 1997, Pages 11-17

  Garcia, Marcel ^a   Derocq, Danielle ^a   Platet, Nadine ^a   Bonnet, Sandrine ^a   Brouillet, Jean Paul ^a   Touitou, Isabelle ^a   Rochefort, Henri ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ESTROGEN ACTIVITY; FEMALE; GENE TRANSFER; HORMONE RESPONSE; IMMUNE RESPONSE; IN VITRO STUDY; METASTASIS; MOUSE; MUTATION; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CELL DIVISION; ESTRADIOL; ESTROGEN ANTAGONISTS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; POLYUNSATURATED ALKAMIDES; RATS; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSFECTION;

ANIMALIA; MUS MUSCULUS;

EID: 0030826962     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00255-5     Document Type: Article

References (22)

1. Rochefort H.: Oestrogens, proteases and breast cancer: from cell lines to clinical applications. Eur. J. Cancer 30A (1994) 1583-1586.
2. McGuire W. L.: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol. 5 (1978) 2428-2433.
3. Levenson A. S. and Jordan V. C.: Transfection of human estrogen receptor cDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Molec. Biol 51 (1994) 229-239.
4. Sheikh M. S., Garcia M., Pujol P., Fontana J. A. and Rochefort H.: Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?. Invas. Metast. 14 (1995) 326-329.
5. Garcia M., Derocq D., Freiss G. and Rochefort H.: Activation of estrogen receptor into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl Acad. Sci. U.S.A. 89 (1992) 11,538-11,542.
6. Zajchowski D. A., Sager R. and Webster L.: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res. 53 (1993) 5004-5011.
7. Green S., Walter P., Kumar V., Krust A., Bornert J., Argos P. Chambon P.: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139.
8. Tora L., Mullick A., Metzer D., Ponglikitmongkol M., Park I. Chambon P.: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 8 (1989) 1981-1986.
9. Jiang S.-Y., Langan-Fahey S. M., Stella A., McCague R. and Jordan V. C.: Point mutation of estrogen receptor (ER) at the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNAs for ER. Molec. Endocr. 6 (1992) 2167-2174.
10. Yamashita T., Yamamoto K., Shiroki K., Kimura G., Matsui K., Osato T., Shimojo H. and Fujinaga K.: Chromosomal alterations of rat cell lines transformed by human adenovirus type-12 virion, whole DNA and leftend DNA fragments. Int. J. Cancer 26 (1980) 435-442.
11. Garcia M., Derocq D., Pujol P. and Rochefort H.: Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5 (1990) 1809-1814.
12. Kissane J. M. and Robbins E.: The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. J. Biol Chem. 233 (1958) 184-188.
13. Albini A., Iwamoto Y., Kleiman H. K., Martin G. R., Aaronson S. A., Kozlowski J. M. and McEwan R. N.: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47 (1987) 3239-3245.
14. Klein-Hitpass L., Schorpp M., Wagner U. R. and Gerhart U. R.: An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46 (1986) 1053-1061.
15. Fawell S. E., White R., Hoare S., Sydenham M., Page M. and Parker M. G.: Inhibition of estrogen receptor-DNA binding by pure antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 6883-6887.
16. Sabbah M., Gouileux F., Sola B., Redeuilh G. and Baulieu E. E.: Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone responsive element. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 390-394.
17. Gronemeyer H., Benhamou B., Berry M., Bocquel M. T., Gofflo D., Garcia T., Metzer D., Meyer M. E., Tora L., Vergezac A. and Chambon P.: Mechanisms of antihormone action. J. Steroid Biochem. Molec. Biol. 41 (1992) 217-221.
18. Friedl A., Gottardis M. M., Pink J., Buchler D. A. and Jordan V. C.: Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice. Cancer Res. 49 (1989) 4758-4764.
19. Kawatsu R., Ezaki T., Kotani M. and Akagi M.: Growth-promoting effect of oestradiol in a lymphoma lacking oestrogen receptor. Br. J. Cancer 59 (1989) 563-568.
20. Friedl A. and Jordan V. C.: Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur. J. Cancer 30A (1994) 1559-1564.
21. Seamen W. E., Blackman M. A., Gindhart T. D., Roubinian J. R., Loeb J. L. and Talal N.: Beta-estradiol reduces natural killer cells in mice. J. Immunol. 121 (1978) 2193-2198.
22. Hrushesky W. J., Bluming A. Z., Gruber S. A. and Sothern R. B.: Menstrual influence on surgical cure of breast cancer. Lancet 2 (1989) 949-952.